Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740795 | 0.99 | KMT2A (0.64) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| Hydrochloric Acid SCHEMBL693423 | 0.92 | KMT2A (0.67) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL697928 | 0.90 | KMT2A (0.73) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL693424 | 0.90 | KMT2A (0.69) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL18376140 | 0.87 | KMT2A (0.64) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| Hydrochloric Acid SCHEMBL31419532 | 0.87 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL20126921 | 0.87 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL92796 | 0.86 | KMT2A (0.66) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL31419531 | 0.86 | KMT2A (0.66) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL31305073 | 0.85 | KMT2A (0.62) | KMT2AEPHX2CASP3CXCR2FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024235133-A1 | POLYCYCLIC DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235120-A1 | FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| WO-2024235130-A1 | POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-9688663-B2 | Crosslinking reagents, methods, and compositions for studying protein-protein interactions | Cell Mosaic, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160159777-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | CELLMOSAIC INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-1984726-B1 | METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION | DH TECHNOLOGIES DEV PTE LTD (SG) | 2015-06-17 | — | — | EP | disclosed |
| US-8975404-B2 | Labeling reagents for analyte determination and methods and compounds used in making the same | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-03-10 | — | — | US | disclosed |
| CN-102933554-A | Crosslinking reagents, methods, and compositions for studying protein-protein interactions | HUANG YUMEI | 2013-02-13 | — | — | CN | disclosed |
| US-20120322978-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | CELLMOSAIC, LLC | 2012-12-20 | — | — | US | disclosed |
| EP-1984726-A2 | METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION | Applera Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070218560-A1 | Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination | APPLERA CORPORATION. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007087534-A2 | METHODS, MIXTURES, KITS AND COMPOSITIONS PERTAINING TO ANALYTE DETERMINATION | APPLERA CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1445250-A1 | NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322978-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | STUB1, PFN1, PFDN1 | OPRD1 4547/4885KMT2A 2126/4885EPHX2 1517/4885 |
| US-20070218560-A1 | Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination | SRMS, CA13, KLK3 | OPRD1 4102/4885KMT2A 2584/4885EPHX2 42/4885 |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | TPSAB1, TPSB2, TPSD1 | OPRD1 779/4885KMT2A 2206/4885EPHX2 1458/4885 |
| US-20160159777-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | PBDC1, RCSD1, STUB1 | OPRD1 2431/4885KMT2A 4097/4885EPHX2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.